FierceBiotech just released its top 15 companies for 2012, called the “2012 Fierce 15.” Several on the list are involved in clinical development relevant for neurodegeneration including En Vivo and Angiochem. Angiochem is targeting diseases of the central nervous system, including Parkinson’s disease and Alzheimer’s disease. These diseases are especially difficult to target because they require passing treatments across the blood brain barrier — however, that’s not stopping Angiochem. This past year, Angiochem partnered with GlaxoSmithKline to break into the rare-disease market, including working on orphan diseases of the brain. This company is one to watch, maybe in 2013 they might think about entering into the ALS space!
Click here to read more.Share this: